<?xml version="1.0" encoding="UTF-8"?>
<p id="p0220">The UK Government, with the UKVN providing evidence and advice, has identified manufacturing infrastructure as a significant bottleneck, and it has sought to invest into a new Vaccine Development and Manufacturing Centre (
 <ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/government/news/medicine-and-vaccine-manufacturing-centres-apply-for-funding" id="ir030" xmlns:xlink="http://www.w3.org/1999/xlink">
  <underline>https://www.gov.uk/government/news/medicine-and-vaccine-manufacturing-centres-apply-for-funding</underline>
 </ext-link>). Other organisations, such as CEPI 
 <xref rid="b0060" ref-type="bibr">[12]</xref>, have also issued calls for proposals into new platform manufacturing technologies (
 <ext-link ext-link-type="uri" xlink:href="http://cepi.net" id="ir035" xmlns:xlink="http://www.w3.org/1999/xlink">cepi.net</ext-link>). The situation exists under the status quo that we may have a vaccine that can be utilised to fight a future epidemic, but not have the manufacturing capacity to enable production and distribution. These latest calls seek to reverse current limitations.
</p>
